IMR Press / FBL / Volume 23 / Issue 6 / DOI: 10.2741/4637

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Precision medicine of frontotemporal dementia: from genotype to phenotype

Show Less
1 Department of Neurology and Neuroscience Institute, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
2 St Vincent’s Hospital, Darlinghurst, Sydney NSW, Australia
Front. Biosci. (Landmark Ed) 2018, 23(6), 1144–1165;
Published: 1 January 2018
(This article belongs to the Special Issue Precision neurology)

Frontotemporal dementia (FTD) is the second most common neurodegenerative cause of early-onset dementia. FTD has an important genetic component contributing to its pathogenic mechanisms. Currently, extensive research on neuroimaging biomarkers and neurochemical biomarkers in FTD is being conducted to address the clinical need for a sensitive and specific diagnostic marker. Here, we review the advances in genetics, biomarkers and treatment of FTD and how this may represent a shift towards precision medicine. To advance the clinical use of precision medicine, big data cohort for genotype/phenotype research and multidisciplinary team approaches are necessary.

Frontotemporal dementia
Frontotemporal Lobar Degeneration
Precision Medicine
Back to top